<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989609</url>
  </required_header>
  <id_info>
    <org_study_id>N-5-2019</org_study_id>
    <nct_id>NCT03989609</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock</brief_title>
  <acronym>RODIS</acronym>
  <official_title>ROle of Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock: Randomized Controlled Trial (RODIS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      in this study the investigators aim to assess the role of using dexmedetomidine as sedative
      in septic shock patients in comparison with midazolam. The investigators aim to assess the
      effect on immune response and inflammatory mediators and effect on vasopressors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sedation protocol All patients will receive analgesia with fentanyl at ﬁxed dose of 0.5
      µg.kg.hr-1. Each patient will receive the study drug within 6 hours after ICU admission.
      Depth of sedation will be assessed using Richmond Agitation and Sedation Scale (RASS) scores
      (6), which range from −5 (unarousable) to +4 (combative). Study treatments will be infused
      without loading dose. Group I patients will have dexmedetomidine (4 µg.mL-1) and group II
      patients will have midazolam (0.33 mg.mL-1). Both drugs will be prepared in 0.9% sodium
      chloride in 50-mL syringe. Both the agents will be titrated to maintain the RASS in a range
      of −3 to −1. Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be
      adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h, while midazolam will be started at 1
      mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1). All
      infusions will be adjusted by increments of 3 mL/hr-1. Patients in either group not
      adequately sedated by study drug titration will receive a bolus dose of fentanyl 0.5-1 µg.kg.
      Assessment of RASS score will be performed every 2 hours and prior to any dose of rescue
      therapy. The study drugs will be infused for 24 hours and after that the choice of sedation
      will be determined according to preference of attending physician.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2019</start_date>
  <completion_date type="Anticipated">March 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CD42/CD14</measure>
    <time_frame>24 hours after start of study drugs infusion</time_frame>
    <description>Expression of CD42/CD14 will be measured by flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect on HLA-DR/CD14</measure>
    <time_frame>Baseline before start of drug then 6, 12 and 24 hour after drug</time_frame>
    <description>Expression of HLA-DR/CD14 will be measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNFα</measure>
    <time_frame>Baseline before start of drug then 6, 12 and 24 hour after drug</time_frame>
    <description>Expression of tumor necrosis factor (TNFα) will be measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL10</measure>
    <time_frame>Baseline before start of drug then 6, 12 and 24 hour after drug</time_frame>
    <description>Interleukin 10 will be measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KIM-1 level</measure>
    <time_frame>Baseline before start of drug and 24 hour after drug</time_frame>
    <description>kidney injury molecule 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants that will die within 28 days</measure>
    <time_frame>within 28 dyas</time_frame>
    <description>mortality within 28 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive dexmedetomidine as sedative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive midazolam as sedative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection [Precedex]</intervention_name>
    <description>Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,</description>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than 18 years old

          -  All mechanically ventilated patients who will be clinically suspected of having septic
             shock defined by infusion of at least one vasopressor and lactate &gt; 2.0 mmol/l (5)

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Pregnant patient

          -  Source of sepsis not controlled

          -  Acute hepatitis or severe liver disease (Child-Pugh class C)

          -  Left ventricular ejection fraction less than 30%

          -  Heart rate less than 50 beats/min

          -  Second or third degree heart block

          -  Systolic pressure &lt; 90 mmHg despite of infusion of 2 vasopressors.

          -  Psychological illness or severe cognitive dysfunction

          -  Patients who are allergic to dexmedetomidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Mohamed Mukhtar, M,D</last_name>
    <role>Study Director</role>
    <affiliation>kasralainy faculty of medicine, Cairo university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Elayashy Mohamed Ahmed Hassan, M.D, FCAI</last_name>
    <phone>00201001833155</phone>
    <email>mohamedelayashy@kasralainy.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>amr hussien Sayed, M.D</last_name>
    <phone>00201223657694</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy Hospital , Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Elayashy Mohamed Ahmed Hassan, M.D, FCAI</last_name>
      <phone>00201001833155</phone>
      <email>mohamedelayashy@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009 Oct;30(10):475-87. doi: 10.1016/j.it.2009.07.009. Epub 2009 Sep 24. Review.</citation>
    <PMID>19781994</PMID>
  </reference>
  <reference>
    <citation>Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci. 2010 Feb;67(4):525-44. doi: 10.1007/s00018-009-0210-4. Epub 2009 Dec 15. Review.</citation>
    <PMID>20013024</PMID>
  </reference>
  <reference>
    <citation>Miranda ML, Balarini MM, Bouskela E. Dexmedetomidine attenuates the microcirculatory derangements evoked by experimental sepsis. Anesthesiology. 2015 Mar;122(3):619-30. doi: 10.1097/ALN.0000000000000491.</citation>
    <PMID>25313879</PMID>
  </reference>
  <reference>
    <citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.</citation>
    <PMID>28101605</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Mohamed Elayashy Mohamed Ahmed Hassan</investigator_full_name>
    <investigator_title>Lecturer of anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

